Citigroup said a bid for the drugmaker was still possible despite the Pfizer cash return
Citigroup said a bid for the drugmaker was still possible despite the Pfizer cash return
Share this Article
Recommended
Citigroup said a bid for the drugmaker was still possible despite the Pfizer cash return